PRUK-supported research projects
Pharmacy Research Showcase highlights Three routes into research At the Pharmacy Research Showcase, three people whose research is supported by Pharmacy Research UK (PRUK) described their own journeys…. read more.
Pharmacy Research Showcase highlights Three routes into research At the Pharmacy Research Showcase, three people whose research is supported by Pharmacy Research UK (PRUK) described their own journeys…. read more.
Egetis Therapeutics AB announced that the FDA has approved Emcitate (tiratricol), a thyroid hormone receptor agonist, for the treatment of peripheral thyrotoxicosis in adults and pediatric patients with… read more.
Olezarsen can be used as an option to treat genetically confirmed familial chylomicronaemia syndrome in adults, only if response to diet and conventional triglyceride-lowering treatments (such as statins… read more.
Mayo Clinic researchers have found that an artificial intelligence (AI) tool may provide dermatologists with additional information to help assess whether skin lesions are cancerous and inform their… read more.
Large language models (LLMs), such as ChatGPT and Claude, are increasingly being used to provide health information to the public. Although this is beneficial for improving access to… read more.
Pharmacy Research Showcase highlights Pharmacy technicians are involved at every point in a medicine’s journey, yet they are rarely involved in research. At the Pharmacy Research Showcase, Panayiotis… read more.
Pharmacy Research Showcase highlights Digital medicines decisions are often made without good evidence, and pharmacy researchers could help fill that gap. That was the challenge Rahul Singal, Chief… read more.
Pharmacy Research Showcase highlights How can a trust make research a normal part of pharmacy work rather than an optional extra? Jatinder Harchowal MBE, Chief Pharmacist and Divisional… read more.
The vast majority of TikTok accounts identified by researchers as connecting drug sellers with potential buyers in the UK remained publicly accessible 14 days after being reported for… read more.
Plozasiran can be used as an option to treat genetically confirmed familial chylomicronaemia syndrome in adults, only if response to diet and conventional triglyceride-lowering treatments (such as statins… read more.
High-nicotine vape use surged by 80% among US 18-24 year olds between 2017 and 2022, and was associated with large increases in daily vaping and nicotine dependence, finds… read more.
AbbVie announced the U.S. Food and Drug Administration has approved a subcutaneous (SC) induction regimen for Skyrizi (risankizumab-rzaa) for adults with moderately to severely active Crohn’s disease (CD)…. read more.